Studies showed that the frequency of tumor-promoting M2 macrophages (CD163+ CD206+) in the bone marrow of AML patients is elevated compared to healthy donors (138) which decreases patient survival (139). This evidence concerns the gene CD163 and acute myeloid leukemia.